{"id":56692,"date":"2026-04-07T13:22:09","date_gmt":"2026-04-07T13:22:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/56692\/"},"modified":"2026-04-07T13:22:09","modified_gmt":"2026-04-07T13:22:09","slug":"novo-nordisk-ups-the-ante-with-wegovy-hd-rollout","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/56692\/","title":{"rendered":"Novo Nordisk Ups the Ante with Wegovy HD Rollout"},"content":{"rendered":"<p>&#13;<\/p>\n<p>In a significant development for the weight-loss drug market, Novo Nordisk has introduced a higher-dose version of its renowned treatment, Wegovy, dubbed Wegovy HD. The drug, which boasts a 7.2 mg dosage, has been made available across the United States.<\/p>\n<p>The new dosage gained approval through the FDA Commissioner&#8217;s National Priority Review Voucher program last month, adding a powerful option to Novo Nordisk&#8217;s portfolio for individuals tackling obesity. Previously, the maximum authorized dosage for Wegovy was 2.4 mg.<\/p>\n<p>Customers, including those without insurance, can now access Wegovy HD through U.S. pharmacies, NovoCare Pharmacy, and select telehealth providers. While cash-paying patients will spend $399 monthly, those insured could pay as little as $25 with savings offers. Novo Nordisk also plans to offer a discounted subscription to remain competitive against Eli Lilly in the obesity-drug market.<\/p>\n<p>&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; In a significant development for the weight-loss drug market, Novo Nordisk has introduced a higher-dose version of&hellip;\n","protected":false},"author":2,"featured_media":56693,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[949,276,7734,4469,272,357,3866,360,1910,280],"class_list":["post-56692","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-drug","tag-eli-lilly","tag-fda-approval","tag-insurance","tag-novo-nordisk","tag-obesity","tag-pharmacies","tag-telehealth","tag-wegovy","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116363640544335103","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/56692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=56692"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/56692\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/56693"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=56692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=56692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=56692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}